Showing results (721-730 of 735) with videos related to
Sort By:
Pageof 74
Cancer Medicine|January 31, 2023
It is not the time to abandon intraoperative frozen section in endometrioid adenocarcinoma: A large-scale, multi-center, and retrospective studyXiaohang Yang, Jingjing Yin, Yu Fu, et al.Nature Medicine|May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Jihong Liu, Jing Wang, et al.The Journal of Clinical Investigation|October 6, 2022
RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancerPeng Deng, Zining Wang, Jinghong Chen, et al.BMC Medicine|May 16, 2024
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancerHuayi Li, Zikun Peng, Jianqing Zhu, et al.JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.Frontiers in Medicine|May 16, 2022
Prognostic-Related Metabolic Score for Survival Prediction in Early-Stage Endometrioid Endometrial Cancer: A Multi-Center and Retrospective StudyZizhuo Wang, Kun Song, Jingbo Liu, et al.Eclinicalmedicine|May 15, 2024
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trialXiaohua Wu, Jianqing Zhu, Rutie Yin, et al.Frontiers in Medicine|November 8, 2021
Implications of Isolated Para-Aortic Lymph Node Metastasis in Endometrial Cancer: A Large-Scale, Multicenter, and Retrospective StudyWenting Li, Jie Jiang, Yu Fu, et al.Nature Communications|December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trialXiaohua Wu, Jing Wang, Danbo Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III TrialNing Li, Youzhong Zhang, Jing Wang, et al.Pageof 74